When is targeted therapy recommended for acute myeloid leukaemia?

AML cells can carry genetic changes that affect how they grow or respond to medicines. Blood and bone-marrow testing identifies changes that may be matched to a targeted drug. Doctors also consider whether treatment is intended to control newly diagnosed disease, maintain a response, treat disease that has returned or manage disease that has not responded to an earlier plan.

Some targeted medicines are combined with chemotherapy; others may be used when intensive chemotherapy is unsuitable or after prior treatment. The choice depends on the exact result, disease phase, previous medicines, blood counts, infections, liver and kidney function, and your ability to attend close monitoring.

Ask whether molecular and chromosome testing has been completed and when the result will change the treatment plan. Give the team a full medicine list, including supplements, because interactions can affect treatment. Keep appointments for blood tests and report new symptoms quickly; AML and its treatments can change blood counts rapidly.

Discuss the intended goal, how response will be measured, and whether a clinical trial, transplant assessment or supportive care should also be considered. Take each medicine exactly as prescribed and never alter a dose without advice.

Call the haematology team promptly for fever, chills, new bleeding, many bruises, severe mouth sores, worsening breathlessness or marked weakness. Go to urgent care for severe breathing difficulty, uncontrolled bleeding, fainting or sudden confusion. Infection can become serious when white blood cell counts are low.

Ask: Which genetic result supports this medicine? Is it being used alone or with chemotherapy? How will we measure response? Which interactions and foods matter? What should I do if I vomit a dose or develop a fever?